What if you could identify high risk patients at the earliest stage of their cardiovascular disease?
VitaK has its own facilities for blood sampling and measuring clinical endpoints in the various human intervention trials that are executed.
Worldwide we are the number one laboratory in measuring Matrix Gla Protein (MGP).
VitaK has a substantial investment program to increase its own clinical equipment for in-house clinical endpoint measurements in human intervention trials and clinical trials.
VitaK Innovation in Life Science has a strong focus on the development of new Point of Care and In Vitro Diagnostic tests.
Both fundamental and applied research are the core business of VitaK. We offer our expertise in the form of contract research for third parties.
The POC testing market is set to reach $49 billion by 2018.
What if you could identify high risk patients at the earliest stage of their cardiovascular disease?
VitaK has its own facilities for blood sampling and measuring clinical endpoints in the various human intervention trials that are executed.
Worldwide we are the number one laboratory in measuring Matrix Gla Protein (MGP).
VitaK has a substantial investment program to increase its own clinical equipment for in-house clinical endpoint measurements in human intervention trials and clinical trials.
VitaK Innovation in Life Science has a strong focus on the development of new Point of Care and In Vitro Diagnostic tests.
Both fundamental and applied research are the core business of VitaK. We offer our expertise in the form of contract research for third parties.
The POC testing market is set to reach $49 billion by 2018.

1988:
Maastricht University founded The Cardiovascular Research Institute Maastricht (CARIM).

2001:
Prof Dr. Cees Vermeer founded Vitak Innovation in Life Science.

2001:
Setting up the division “Innovation and Research”

2002:
Setting up the division “Clinical Research Organisation”

2006:
Our expertise and infrastructure for executing human intervention trials was made available for third parties in the food-, pharmaceutical-, and medical devices industry.

2007:
A Consultancy branch for the nutritional and pharmaceutical industry was established, with senior scientists providing consultancy on a regular basis.

2010:
Vitak Innovation in Life Science reported a conformation-specific Assay for Vascular Matrix Gla-Protein (MGP) which is predictive for cardiovascular mortality both in various patient groups and in the healthy population.

2010:
Vitak Innovation in Life Science focused on the development of Point of Care and In Vitro Diagnostics.

2012:
Our specialized diagnostic facilities were expanded with a Routine Diagnostics Service in which both newly developed biomarkers and commercially available markers are routinely tested for third parties (mainly academic groups as well as the food-, pharmaceutical-, and medical devices industry).

2014:
Opening of our office in the United Arab Emirates.

2016:
Introduction of Vita K Meter (Point of Care)

2016:
Introduction of TransCare (In Vitro Diagnostics)

2017:
Introduction Nephro-K (In Vitro Diagnostics)

2017:
Introduction of StiffnoGraph (Point of Care)

Head office:
Oxfordlaan 55
6229 EV Maastricht
The Netherlands
T: +31 (0)43 388 5926

Laboratories:
Oxfordlaan 70
6229 EV Maastricht
The Netherlands
E: info@vitak.com